Prescription Medicines
Glimin Tab.
- Product Category
- Oral hypoglycemic agents
- Active Ingredients
- glimepiride
- Appearance
- green, oblong tablets
- Reimbursement Code
- 648100290
01 / 02
1. Composition and Strength
1 tablet
- Active ingredient: Glimepiride (EP)----2mg
- Additive (tar color aluminum lake): Blue No. 2
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, iron oxide, magnesium stearate, sodium starch glycolate, povidone
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
1. This drug is administered as monotherapy.
2. This drug is administered as combination therapy in the following cases.
1) If blood sugar control is not adequately achieved with oral hypoglycemic agents, combined administration with insulin
2) If blood sugar control is not adequately achieved with sulfonylurea or metformin monotherapy, administer this drug in combination with metformin.
3. Dosage and dosage
Adjust individually for each patient. Swallow without chewing with at least 1/2 cup of water. This drug is administered orally once a day. This medication should be taken before breakfast or just before the first meal. It is very important not to skip meals after taking this medicine.
1. Monotherapy
1) Determination of initial capacity and capacity
For patients who have not previously received medication, start treatment with 1 mg of glimepiride once a day. If necessary, increase the dose by 1 mg at intervals of 1 to 2 weeks. In general, there is little additional effect when administered at doses above 4 mg, but some patients have shown better metabolic control by increasing the dose up to 6 mg (or 8 mg). If 4 mg per day fails, first consider switching to insulin therapy, and if not, consider combination use with insulin or other oral antidiabetic drugs.
2) Secondary capacity adjustment
As treatment progresses and diabetes control improves, the need for this drug may decrease. Therefore, a dose reduction or discontinuation of this drug may be necessary to avoid hypoglycemia. Dosage adjustments should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of developing hypoglycemia or hyperglycemia.
3) Switching from other oral hypoglycemic agents to this drug
There is no exact dosage relationship between this drug and other oral hypoglycemic agents. When switching to this drug while taking other oral hypoglycemic agents, it is recommended to follow the method suggested in the initial dosage section. In other words, you can start administration with 1 mg per day and adjust the dose at intervals of 1 to 2 weeks. The efficacy and duration of action of previously administered drugs must be taken into consideration.
4) Dosage adjustment
While taking this medicine, your blood sugar or/and urine sugar levels should be measured regularly, and it is also recommended that your glycated hemoglobin (HbA1c) level be measured regularly. Typically, low blood sugar is immediately controlled by consuming sugar immediately. When sulfonylurea drugs are administered, hypoglycemia may recur despite initial successful treatment. Therefore, patients must be observed carefully. In cases of severe hypoglycemia, immediate treatment and follow-up by a doctor are required, and sometimes hospitalization is required.
2. Combination therapy
1) Combination therapy with insulin
Combination therapy with this drug and insulin is used for patients with secondary failure. Combination therapy with insulin is used when fasting blood sugar (FBG) exceeds 150 mg/dL. This drug is administered at 8 mg once a day with the first meal, and the insulin dose is started at a low dose and increased at approximately weekly intervals according to fasting blood sugar measurements. Once stabilized, capillary blood sugar should be monitored daily if possible. It is necessary to periodically adjust the dose of insulin while measuring blood sugar and glycated hemoglobin.
2) Combination therapy with metformin
If the patient does not respond adequately to the maximum dose of this medicine, adding metformin may be considered. Published clinical data are available on metformin combined with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide and tolbutamide. When this medicine is combined with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to identify the lowest effective dose of each medicine for glycemic control. Hypoglycemia can occur with this combination, and the risk may be increased. Appropriate precautions should be taken.
4. Precautions for use
1. Do not administer to the following patients.
1) Insulin-dependent (type 1) diabetic patients (e.g., diabetic patients with a history of ketonemia), diabetic ketonemia, diabetic coma, or precoma
2) Patients with a history of hypersensitivity to this drug, its components, or sulfonylurea or sulfonamide drugs
3) Patients with severe liver dysfunction or severe renal dysfunction (no experience with use. In patients with severe liver dysfunction or renal dysfunction, switching to insulin therapy is recommended to achieve optimal blood sugar control.)
4) Pregnant women or women who may be pregnant and lactating women
5) Patients with severe infection, before or after surgery, or severe trauma (insulin therapy is applied) (refer to general precautions)
6) Patients with gastrointestinal disorders such as diarrhea and vomiting (there is a risk of hypoglycemia due to malabsorption of food).
2. Administer with caution to the following patients (cases):
The risk of hypoglycemia is high during the first week of medication, so careful monitoring is necessary. Patients or conditions at high risk for developing hypoglycemia include:
1) Patients who are uncooperative or unable to cooperate (more common in elderly people)
2) Patients with malnutrition, irregular meal intake, or skipping meals
3) Patients whose muscle exercise and carbohydrate intake are unbalanced
4) If you change your diet
5) Alcohol drinkers, especially patients who skip meals
6) Patients with renal dysfunction (may be more sensitive to the blood sugar-lowering effect of this drug)
7) Patients with liver dysfunction
8) Patients who overdosed on this drug
9) Decompensated endocrine diseases (e.g., patients with thyroid abnormalities, anterior pituitary dysfunction, or adrenocortical insufficiency): These diseases may affect glucose metabolism or the body's counterregulation of hypoglycemia.
10) Elderly people
11) Concurrent administration with other drugs (refer to the interaction section)
In these cases, it is necessary to monitor blood sugar levels particularly carefully, so patients should inform their doctor or pharmacist about these factors and whether they have ever experienced symptoms of hypoglycemia. If these risk factors for hypoglycemia exist, it is necessary to adjust the dose or the entire medication regimen. This also applies if other diseases occur during medication administration or if the patient's lifestyle changes. In patients with progressively advanced hypoglycemia, the elderly, patients with autonomic neuropathy, or patients receiving concomitant treatment with beta-blockers, clonidine, reserpine, guanethidine, or other sympathetic nerve blockers, the symptoms of hypoglycemia (see Adverse Reactions section) due to the body's adrenergic counterregulation may be alleviated or may not appear.
3. Adverse reactions
According to the clinical trial results of this drug and information on other sulfonylurea drugs, the following adverse reactions should be considered.
1) Hypoglycemia: Hypoglycemia may occur or be prolonged as a result of the blood sugar lowering effect of this drug. Symptoms of hypoglycemia include headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbance, anxiety, aggression, decreased concentration, decreased agility or mobility, depression, confusion, speech abnormality, aphasia, visual impairment, tremor, paresis, paresthesia, dizziness, helplessness, loss of control, temporary delirium, cerebral convulsions, drowsiness, loss of consciousness and coma, shallow breathing, and bradycardia. Additionally, symptoms of adrenergic counterregulation may include sweating, cold and moist skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris, and cardiac arrhythmia. The clinical symptoms of severe hypoglycemia are similar to stroke. In most cases, once hypoglycemia is corrected, clinical symptoms disappear.
2) Eyes: Temporary visual abnormalities such as changes in regulation and blurred vision may occur due to changes in blood sugar levels, especially in the early stages of administration.
3) Gastrointestinal system: Occasionally, digestive symptoms such as nausea, vomiting, fullness or pressure in the upper abdomen, abdominal pain, and diarrhea may appear.
4) Liver: Unknown increase in intrahepatic enzymes, and in very rare cases liver dysfunction (e.g. bile secretion disorder, jaundice) and hepatitis may occur. This may lead to liver dysfunction, so observe thoroughly. If abnormalities appear, stop administration and take appropriate measures.
5) Blood system: Serious blood changes may occur. Rarely, thrombocytopenia, and very rarely, leukopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis, or pancytopenia may occur. There have been reports of aplastic anemia occurring with other sulfonylurea drugs, so observe thoroughly, and if adverse reactions occur, discontinue administration and take appropriate measures.
Although the frequency is unknown in post-marketing experience, severe thrombocytopenia accompanied by platelet counts less than 10,000/μL and thrombocytopenic purpura has been reported.
6) Hypersensitivity reaction: Sometimes allergies or allergic-like reactions (e.g. itching, hives, rash, etc.) may occur.
Most of these reactions are mild, but they can develop into serious reactions accompanied by difficulty breathing, a drop in blood pressure, etc., and sometimes progress to shock. Therefore, if hives appear, you should immediately notify your doctor. Cross-allergic reactions with sulfonylureas, sulfonamides and their derivatives may occur.
In post-marketing surveillance, hypersensitivity reactions, including serious reactions such as anaphylaxis, angioedema, and mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), have been reported in patients treated with this drug. If such a reaction is suspected, discontinue this drug immediately, evaluate other potential causes for the reaction, and initiate other treatment for diabetes.
7) Others: It is known that allergic vasculitis, skin photosensitivity reaction, and decreased serum sodium concentration may occur in very rare cases.
If any of the adverse reactions listed above, other undesirable reactions, or unexpected changes occur, you must notify your doctor or pharmacist. Some adverse reactions, such as severe hypoglycemia, certain changes in the blood, severe allergic or allergic-like reactions, and liver failure, may be life-threatening in certain circumstances. If an unexpected or serious reaction occurs, notify your doctor immediately and stop taking the drug until instructed. As a result of post-marketing surveillance, taste disorders, hair loss, and weight gain were reported in patients treated with this drug. (frequency unknown)
8) As a result of a post-marketing survey conducted on 12,056 people over 6 years in Korea, the frequency of adverse reactions was reported to be 1.2% (149 people/12,056 people) regardless of causal relationship. Hypoglycemia was the most common at 0.75% (102 cases, 90 people), followed by dizziness at 0.08% (10 people), liver dysfunction at 0.07% (8 people), and abdominal pain at 0.06% (7 people). Among these, new adverse reactions that did not appear in pre-market clinical trials were reported in 2 cases each of joint pain, indigestion, and facial edema, and in 1 case each of impotence, hair loss, facial flushing, and gastritis.
4. General precautions
1) In order to achieve optimal blood sugar control, you must not only take this drug regularly, but also diet, exercise, and, if necessary, lose weight. Clinical signs of insufficient blood sugar control (hyperglycemia) include frequent urination, thirst, dry mouth, and dry skin.
2) When starting medication, the doctor or pharmacist must inform the patient of the effects and risks of this drug and the effects of this drug when combined with diet and exercise therapy, and also emphasize the importance of the patient's active cooperation.
3) Hypoglycemia is mostly immediately controlled by consuming sugar (glucose or sugar, such as sugar lumps, fruit juice with added sugar, tea with added sugar, etc.). For this purpose, patients must always carry at least 20 g of sugar. The risks, symptoms and treatment of hypoglycemia, and the causes of hypoglycemia are explained to the patient and the patient's family. You may need the help of another person to avoid complications. Artificial sweeteners are not effective in controlling low blood sugar.
4) When sulfonylurea drugs are administered, hypoglycemia may recur despite initial successful treatment. Therefore, doctors or pharmacists must carefully observe patients. In cases of severe hypoglycemia, active treatment and follow-up by a doctor are required, and in some cases, hospitalization is required.
5) When receiving treatment from another doctor or pharmacist (e.g., when hospitalized, after an accident, when sick on a public holiday, etc.), the patient must inform them of his/her diabetes status and previous medication experience.
6) Since glycemic control may worsen under exceptional stress conditions (e.g., trauma, surgery, febrile infection), temporarily switch to insulin therapy to maintain appropriate glycemic control.
7) When administering, start with a small amount, and regularly check blood sugar and urine sugar (it is also recommended to measure the ratio of glycated hemoglobin (HbA1c) regularly). Check the effectiveness of the drug and if the effect is insufficient, quickly change to another treatment.
8) Especially in the early stages of administration, after changing the administered medication, or when this drug is not taken regularly, dexterity disorders and behavioral disorders due to hypoglycemia or hyperglycemia may occur, which may affect driving ability, ability to operate machinery, etc.
9) According to a study by the University Group Deabetes Program (UGDP), when sulfonylurea drugs (1.5 g per day of tolbutamide) were administered long-term, the mortality rate due to cardiovascular disorders was found to be significantly higher compared to diet therapy alone or diet therapy and insulin combined administration.
10) Hemolytic anemia: When patients with G6PD deficiency take sulfonylurea drugs, hemolytic anemia may occur. Since glimepiride belongs to the sulfonylurea class, caution should be exercised when administering it to patients with G6PD deficiency, and replacement with a non-sulfonylurea drug should be considered.
5. Interaction
Blood sugar control may change in patients who take other medications concomitantly or who stop taking other medications while taking this drug. According to experience using this drug or other sulfonylurea drugs, the following interactions should be considered.
1) This drug is metabolized by CYP2C9. Therefore, these matters should be taken into consideration when co-administering this drug with CYP2C9 inducers (e.g., rifampicin) or inhibitors (e.g., fluconazole).
2) Drugs that increase blood sugar lowering effect: Insulin preparations and other oral hypoglycemic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors, allopurinol, anabolic steroids, male hormones, chloramphenicol, coumarin anticoagulants, cyclophosphamide, disopyramide, fenfluramine, peniramidol, fibrate drugs, fluoxetine, Guanethidine, ifosfamide, MAO inhibitors, miconazole, fluconazole, para-aminosalicylic acid, pentoxifylline (when administered parenterally in high doses), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolone antibacterial agents, salicylates, sulfinpyrazone, clarithromycin, sulfonamide, tetracycline Antibiotics, tritoqualin, troposphamide, sympathomimetics
3) Drugs that reduce blood sugar lowering action: acetazolamide, barbituric acid drugs, corticosteroids, diazoxide, diuretics, epinephrine (adrenaline) or other sympathomimetics, glucagon, laxatives (after long-term use), nicotinic acid (when administered in high doses) and nicotinic acid derivatives, estrogens, progestogens, oral contraceptives, phenothiazines. Drugs, phenytoin, rifampicin, thyroid hormones, chlorpromazine, isoniazid
4) Drugs that increase or decrease blood sugar lowering effect: H2 receptor antagonist, beta blocker, clonidine, reserpine
5) Beta blockers reduce glucose tolerance. Reduced glucose tolerance in diabetic patients may alter metabolic regulation. Beta-blockers may increase the risk of developing hypoglycemia (due to failure of counterregulation).
6) Drugs that reduce or block the body's signs of adrenergic counterregulation in response to hypoglycemia: Sympathetic nerve blockers (e.g. beta-blockers, clonidine, guanethidine, reserpine, etc.)
7) Acute or chronic alcohol consumption may increase or decrease the blood sugar-lowering effect of this drug in an unpredictable way.
8) Concurrent administration of this drug may increase or decrease the effect of coumarin anticoagulants.
9) Bile acid adsorbent: Colesevelam binds to glimepiride and reduces the absorption of glimepiride in the gastrointestinal tract. No interaction was observed when glimepiride was administered at least 4 hours before Colesevelam. Therefore, glimepiride should be taken at least 4 hours before taking Colesevelam.
6. Administration to pregnant and lactating women
1) This drug should not be administered to pregnant women as it may cause harm to the fetus. Patients who are pregnant or plan to become pregnant are advised to notify their doctor and switch to insulin therapy.
2) In a reproduction test on rats, significant concentrations of glimepiride were observed in the serum and milk of the mother and the serum of the offspring. Since sulfonylurea is secreted in human milk, it should not be administered to breastfeeding women to prevent newborns from ingesting this drug through breast milk. If necessary, switch to insulin therapy or discontinue breast-feeding.
3) In some tests on rats, offspring of rats exposed to high doses of glimepiride during pregnancy and lactation showed skeletal deformities such as shortening, thickening, and curvature of the humerus.
7. Administration to children
Safety and efficacy have not been established in pediatric patients under 18 years of age.
8. Administration to elderly people
Since this drug is excreted in significant amounts through the kidneys, caution should be exercised in dose selection when administering to elderly patients with reduced renal function.
9. Treatment in case of overdose
Overdosage of this drug may cause hypoglycemia. To prevent gastric absorption of this drug, initially induce vomiting and then have the patient drink a lot of water or soft drinks containing activated charcoal (adsorbent) and sodium sulfate (laxative). If a significant amount is absorbed, gastric lavage should be performed and activated charcoal and sodium sulfate should be used later.
If the overdose is severe and hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous infusion of concentrated (50%) glucose infusion. Afterwards, a more diluted (10%) glucose solution is administered continuously at a rate that can maintain the blood sugar level above 100 mg/dL. Because hypoglycemia may recur even after apparent clinical recovery, patients should be monitored closely for at least 24 to 48 hours.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container and keep it tightly closed.
11. Others
1) In experiments conducted on rats administered on a complete diet for 30 months at doses up to 5,000 ppm (approximately 340 times the maximum recommended dose for humans based on surface area), there was no evidence of carcinogenicity. Administration of glimepiride for 24 months in mice resulted in an increase in benign pancreatic adenomas, which was believed to be a result of dose-related chronic stimulation of the pancreas. In this experiment, the no-effect dose on adenoma formation in mice was 320 ppm or 46 to 54 mg/kg/day under complete diet conditions. Based on surface area, this is approximately 35 times the maximum recommended dose for humans of 8 mg once daily.
2) Glimepiride showed no mutations in a series of in vitro and in vivo mutation experiments.
3) There was no effect of glimepiride on fertility in male mice exposed at doses up to 2,500 mg/kg (>1,700 times the maximum recommended human dose based on surface area). Glimepiride did not affect fertility in male and female rats when administered at doses up to 4,000 mg/kg (approximately 4,000 times the maximum recommended human dose based on surface area).
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
1 tablet
- Active ingredient: Glimepiride (EP)----2mg
- Additive (tar color aluminum lake): Blue No. 2
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: microcrystalline cellulose, iron oxide, magnesium stearate, sodium starch glycolate, povidone
2. Effectiveness
This drug is administered as an adjunct to diet and exercise therapy to improve blood sugar control in patients with type 2 diabetes.
1. This drug is administered as monotherapy.
2. This drug is administered as combination therapy in the following cases.
1) If blood sugar control is not adequately achieved with oral hypoglycemic agents, combined administration with insulin
2) If blood sugar control is not adequately achieved with sulfonylurea or metformin monotherapy, administer this drug in combination with metformin.
3. Dosage and dosage
Adjust individually for each patient. Swallow without chewing with at least 1/2 cup of water. This drug is administered orally once a day. This medication should be taken before breakfast or just before the first meal. It is very important not to skip meals after taking this medicine.
1. Monotherapy
1) Determination of initial capacity and capacity
For patients who have not previously received medication, start treatment with 1 mg of glimepiride once a day. If necessary, increase the dose by 1 mg at intervals of 1 to 2 weeks. In general, there is little additional effect when administered at doses above 4 mg, but some patients have shown better metabolic control by increasing the dose up to 6 mg (or 8 mg). If 4 mg per day fails, first consider switching to insulin therapy, and if not, consider combination use with insulin or other oral antidiabetic drugs.
2) Secondary capacity adjustment
As treatment progresses and diabetes control improves, the need for this drug may decrease. Therefore, a dose reduction or discontinuation of this drug may be necessary to avoid hypoglycemia. Dosage adjustments should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of developing hypoglycemia or hyperglycemia.
3) Switching from other oral hypoglycemic agents to this drug
There is no exact dosage relationship between this drug and other oral hypoglycemic agents. When switching to this drug while taking other oral hypoglycemic agents, it is recommended to follow the method suggested in the initial dosage section. In other words, you can start administration with 1 mg per day and adjust the dose at intervals of 1 to 2 weeks. The efficacy and duration of action of previously administered drugs must be taken into consideration.
4) Dosage adjustment
While taking this medicine, your blood sugar or/and urine sugar levels should be measured regularly, and it is also recommended that your glycated hemoglobin (HbA1c) level be measured regularly. Typically, low blood sugar is immediately controlled by consuming sugar immediately. When sulfonylurea drugs are administered, hypoglycemia may recur despite initial successful treatment. Therefore, patients must be observed carefully. In cases of severe hypoglycemia, immediate treatment and follow-up by a doctor are required, and sometimes hospitalization is required.
2. Combination therapy
1) Combination therapy with insulin
Combination therapy with this drug and insulin is used for patients with secondary failure. Combination therapy with insulin is used when fasting blood sugar (FBG) exceeds 150 mg/dL. This drug is administered at 8 mg once a day with the first meal, and the insulin dose is started at a low dose and increased at approximately weekly intervals according to fasting blood sugar measurements. Once stabilized, capillary blood sugar should be monitored daily if possible. It is necessary to periodically adjust the dose of insulin while measuring blood sugar and glycated hemoglobin.
2) Combination therapy with metformin
If the patient does not respond adequately to the maximum dose of this medicine, adding metformin may be considered. Published clinical data are available on metformin combined with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide and tolbutamide. When this medicine is combined with metformin, the desired blood glucose level may be achieved by adjusting the dose of each medicine. However, efforts should be made to identify the lowest effective dose of each medicine for glycemic control. Hypoglycemia can occur with this combination, and the risk may be increased. Appropriate precautions should be taken.
4. Precautions for use
1. Do not administer to the following patients.
1) Insulin-dependent (type 1) diabetic patients (e.g., diabetic patients with a history of ketonemia), diabetic ketonemia, diabetic coma, or precoma
2) Patients with a history of hypersensitivity to this drug, its components, or sulfonylurea or sulfonamide drugs
3) Patients with severe liver dysfunction or severe renal dysfunction (no experience with use. In patients with severe liver dysfunction or renal dysfunction, switching to insulin therapy is recommended to achieve optimal blood sugar control.)
4) Pregnant women or women who may be pregnant and lactating women
5) Patients with severe infection, before or after surgery, or severe trauma (insulin therapy is applied) (refer to general precautions)
6) Patients with gastrointestinal disorders such as diarrhea and vomiting (there is a risk of hypoglycemia due to malabsorption of food).
2. Administer with caution to the following patients (cases):
The risk of hypoglycemia is high during the first week of medication, so careful monitoring is necessary. Patients or conditions at high risk for developing hypoglycemia include:
1) Patients who are uncooperative or unable to cooperate (more common in elderly people)
2) Patients with malnutrition, irregular meal intake, or skipping meals
3) Patients whose muscle exercise and carbohydrate intake are unbalanced
4) If you change your diet
5) Alcohol drinkers, especially patients who skip meals
6) Patients with renal dysfunction (may be more sensitive to the blood sugar-lowering effect of this drug)
7) Patients with liver dysfunction
8) Patients who overdosed on this drug
9) Decompensated endocrine diseases (e.g., patients with thyroid abnormalities, anterior pituitary dysfunction, or adrenocortical insufficiency): These diseases may affect glucose metabolism or the body's counterregulation of hypoglycemia.
10) Elderly people
11) Concurrent administration with other drugs (refer to the interaction section)
In these cases, it is necessary to monitor blood sugar levels particularly carefully, so patients should inform their doctor or pharmacist about these factors and whether they have ever experienced symptoms of hypoglycemia. If these risk factors for hypoglycemia exist, it is necessary to adjust the dose or the entire medication regimen. This also applies if other diseases occur during medication administration or if the patient's lifestyle changes. In patients with progressively advanced hypoglycemia, the elderly, patients with autonomic neuropathy, or patients receiving concomitant treatment with beta-blockers, clonidine, reserpine, guanethidine, or other sympathetic nerve blockers, the symptoms of hypoglycemia (see Adverse Reactions section) due to the body's adrenergic counterregulation may be alleviated or may not appear.
3. Adverse reactions
According to the clinical trial results of this drug and information on other sulfonylurea drugs, the following adverse reactions should be considered.
1) Hypoglycemia: Hypoglycemia may occur or be prolonged as a result of the blood sugar lowering effect of this drug. Symptoms of hypoglycemia include headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbance, anxiety, aggression, decreased concentration, decreased agility or mobility, depression, confusion, speech abnormality, aphasia, visual impairment, tremor, paresis, paresthesia, dizziness, helplessness, loss of control, temporary delirium, cerebral convulsions, drowsiness, loss of consciousness and coma, shallow breathing, and bradycardia. Additionally, symptoms of adrenergic counterregulation may include sweating, cold and moist skin, anxiety, tachycardia, hypertension, palpitations, angina pectoris, and cardiac arrhythmia. The clinical symptoms of severe hypoglycemia are similar to stroke. In most cases, once hypoglycemia is corrected, clinical symptoms disappear.
2) Eyes: Temporary visual abnormalities such as changes in regulation and blurred vision may occur due to changes in blood sugar levels, especially in the early stages of administration.
3) Gastrointestinal system: Occasionally, digestive symptoms such as nausea, vomiting, fullness or pressure in the upper abdomen, abdominal pain, and diarrhea may appear.
4) Liver: Unknown increase in intrahepatic enzymes, and in very rare cases liver dysfunction (e.g. bile secretion disorder, jaundice) and hepatitis may occur. This may lead to liver dysfunction, so observe thoroughly. If abnormalities appear, stop administration and take appropriate measures.
5) Blood system: Serious blood changes may occur. Rarely, thrombocytopenia, and very rarely, leukopenia, hemolytic anemia, erythrocytopenia, granulocytopenia, agranulocytosis, or pancytopenia may occur. There have been reports of aplastic anemia occurring with other sulfonylurea drugs, so observe thoroughly, and if adverse reactions occur, discontinue administration and take appropriate measures.
Although the frequency is unknown in post-marketing experience, severe thrombocytopenia accompanied by platelet counts less than 10,000/μL and thrombocytopenic purpura has been reported.
6) Hypersensitivity reaction: Sometimes allergies or allergic-like reactions (e.g. itching, hives, rash, etc.) may occur.
Most of these reactions are mild, but they can develop into serious reactions accompanied by difficulty breathing, a drop in blood pressure, etc., and sometimes progress to shock. Therefore, if hives appear, you should immediately notify your doctor. Cross-allergic reactions with sulfonylureas, sulfonamides and their derivatives may occur.
In post-marketing surveillance, hypersensitivity reactions, including serious reactions such as anaphylaxis, angioedema, and mucocutaneous ophthalmic syndrome (Stevens-Johnson syndrome), have been reported in patients treated with this drug. If such a reaction is suspected, discontinue this drug immediately, evaluate other potential causes for the reaction, and initiate other treatment for diabetes.
7) Others: It is known that allergic vasculitis, skin photosensitivity reaction, and decreased serum sodium concentration may occur in very rare cases.
If any of the adverse reactions listed above, other undesirable reactions, or unexpected changes occur, you must notify your doctor or pharmacist. Some adverse reactions, such as severe hypoglycemia, certain changes in the blood, severe allergic or allergic-like reactions, and liver failure, may be life-threatening in certain circumstances. If an unexpected or serious reaction occurs, notify your doctor immediately and stop taking the drug until instructed. As a result of post-marketing surveillance, taste disorders, hair loss, and weight gain were reported in patients treated with this drug. (frequency unknown)
8) As a result of a post-marketing survey conducted on 12,056 people over 6 years in Korea, the frequency of adverse reactions was reported to be 1.2% (149 people/12,056 people) regardless of causal relationship. Hypoglycemia was the most common at 0.75% (102 cases, 90 people), followed by dizziness at 0.08% (10 people), liver dysfunction at 0.07% (8 people), and abdominal pain at 0.06% (7 people). Among these, new adverse reactions that did not appear in pre-market clinical trials were reported in 2 cases each of joint pain, indigestion, and facial edema, and in 1 case each of impotence, hair loss, facial flushing, and gastritis.
4. General precautions
1) In order to achieve optimal blood sugar control, you must not only take this drug regularly, but also diet, exercise, and, if necessary, lose weight. Clinical signs of insufficient blood sugar control (hyperglycemia) include frequent urination, thirst, dry mouth, and dry skin.
2) When starting medication, the doctor or pharmacist must inform the patient of the effects and risks of this drug and the effects of this drug when combined with diet and exercise therapy, and also emphasize the importance of the patient's active cooperation.
3) Hypoglycemia is mostly immediately controlled by consuming sugar (glucose or sugar, such as sugar lumps, fruit juice with added sugar, tea with added sugar, etc.). For this purpose, patients must always carry at least 20 g of sugar. The risks, symptoms and treatment of hypoglycemia, and the causes of hypoglycemia are explained to the patient and the patient's family. You may need the help of another person to avoid complications. Artificial sweeteners are not effective in controlling low blood sugar.
4) When sulfonylurea drugs are administered, hypoglycemia may recur despite initial successful treatment. Therefore, doctors or pharmacists must carefully observe patients. In cases of severe hypoglycemia, active treatment and follow-up by a doctor are required, and in some cases, hospitalization is required.
5) When receiving treatment from another doctor or pharmacist (e.g., when hospitalized, after an accident, when sick on a public holiday, etc.), the patient must inform them of his/her diabetes status and previous medication experience.
6) Since glycemic control may worsen under exceptional stress conditions (e.g., trauma, surgery, febrile infection), temporarily switch to insulin therapy to maintain appropriate glycemic control.
7) When administering, start with a small amount, and regularly check blood sugar and urine sugar (it is also recommended to measure the ratio of glycated hemoglobin (HbA1c) regularly). Check the effectiveness of the drug and if the effect is insufficient, quickly change to another treatment.
8) Especially in the early stages of administration, after changing the administered medication, or when this drug is not taken regularly, dexterity disorders and behavioral disorders due to hypoglycemia or hyperglycemia may occur, which may affect driving ability, ability to operate machinery, etc.
9) According to a study by the University Group Deabetes Program (UGDP), when sulfonylurea drugs (1.5 g per day of tolbutamide) were administered long-term, the mortality rate due to cardiovascular disorders was found to be significantly higher compared to diet therapy alone or diet therapy and insulin combined administration.
10) Hemolytic anemia: When patients with G6PD deficiency take sulfonylurea drugs, hemolytic anemia may occur. Since glimepiride belongs to the sulfonylurea class, caution should be exercised when administering it to patients with G6PD deficiency, and replacement with a non-sulfonylurea drug should be considered.
5. Interaction
Blood sugar control may change in patients who take other medications concomitantly or who stop taking other medications while taking this drug. According to experience using this drug or other sulfonylurea drugs, the following interactions should be considered.
1) This drug is metabolized by CYP2C9. Therefore, these matters should be taken into consideration when co-administering this drug with CYP2C9 inducers (e.g., rifampicin) or inhibitors (e.g., fluconazole).
2) Drugs that increase blood sugar lowering effect: Insulin preparations and other oral hypoglycemic drugs, non-steroidal anti-inflammatory drugs (NSAIDs), ACE inhibitors, allopurinol, anabolic steroids, male hormones, chloramphenicol, coumarin anticoagulants, cyclophosphamide, disopyramide, fenfluramine, peniramidol, fibrate drugs, fluoxetine, Guanethidine, ifosfamide, MAO inhibitors, miconazole, fluconazole, para-aminosalicylic acid, pentoxifylline (when administered parenterally in high doses), phenylbutazone, azapropazone, oxyphenbutazone, probenecid, quinolone antibacterial agents, salicylates, sulfinpyrazone, clarithromycin, sulfonamide, tetracycline Antibiotics, tritoqualin, troposphamide, sympathomimetics
3) Drugs that reduce blood sugar lowering action: acetazolamide, barbituric acid drugs, corticosteroids, diazoxide, diuretics, epinephrine (adrenaline) or other sympathomimetics, glucagon, laxatives (after long-term use), nicotinic acid (when administered in high doses) and nicotinic acid derivatives, estrogens, progestogens, oral contraceptives, phenothiazines. Drugs, phenytoin, rifampicin, thyroid hormones, chlorpromazine, isoniazid
4) Drugs that increase or decrease blood sugar lowering effect: H2 receptor antagonist, beta blocker, clonidine, reserpine
5) Beta blockers reduce glucose tolerance. Reduced glucose tolerance in diabetic patients may alter metabolic regulation. Beta-blockers may increase the risk of developing hypoglycemia (due to failure of counterregulation).
6) Drugs that reduce or block the body's signs of adrenergic counterregulation in response to hypoglycemia: Sympathetic nerve blockers (e.g. beta-blockers, clonidine, guanethidine, reserpine, etc.)
7) Acute or chronic alcohol consumption may increase or decrease the blood sugar-lowering effect of this drug in an unpredictable way.
8) Concurrent administration of this drug may increase or decrease the effect of coumarin anticoagulants.
9) Bile acid adsorbent: Colesevelam binds to glimepiride and reduces the absorption of glimepiride in the gastrointestinal tract. No interaction was observed when glimepiride was administered at least 4 hours before Colesevelam. Therefore, glimepiride should be taken at least 4 hours before taking Colesevelam.
6. Administration to pregnant and lactating women
1) This drug should not be administered to pregnant women as it may cause harm to the fetus. Patients who are pregnant or plan to become pregnant are advised to notify their doctor and switch to insulin therapy.
2) In a reproduction test on rats, significant concentrations of glimepiride were observed in the serum and milk of the mother and the serum of the offspring. Since sulfonylurea is secreted in human milk, it should not be administered to breastfeeding women to prevent newborns from ingesting this drug through breast milk. If necessary, switch to insulin therapy or discontinue breast-feeding.
3) In some tests on rats, offspring of rats exposed to high doses of glimepiride during pregnancy and lactation showed skeletal deformities such as shortening, thickening, and curvature of the humerus.
7. Administration to children
Safety and efficacy have not been established in pediatric patients under 18 years of age.
8. Administration to elderly people
Since this drug is excreted in significant amounts through the kidneys, caution should be exercised in dose selection when administering to elderly patients with reduced renal function.
9. Treatment in case of overdose
Overdosage of this drug may cause hypoglycemia. To prevent gastric absorption of this drug, initially induce vomiting and then have the patient drink a lot of water or soft drinks containing activated charcoal (adsorbent) and sodium sulfate (laxative). If a significant amount is absorbed, gastric lavage should be performed and activated charcoal and sodium sulfate should be used later.
If the overdose is severe and hypoglycemic coma is diagnosed or suspected, the patient should be given a rapid intravenous infusion of concentrated (50%) glucose infusion. Afterwards, a more diluted (10%) glucose solution is administered continuously at a rate that can maintain the blood sugar level above 100 mg/dL. Because hypoglycemia may recur even after apparent clinical recovery, patients should be monitored closely for at least 24 to 48 hours.
10. Precautions for storage and handling
1) Keep out of reach of children.
2) Taking medicine out of its original container and storing it in another container may cause an accident due to misuse of the medicine or cause a decrease in the quality of the medicine, so keep it in the original container and keep it tightly closed.
11. Others
1) In experiments conducted on rats administered on a complete diet for 30 months at doses up to 5,000 ppm (approximately 340 times the maximum recommended dose for humans based on surface area), there was no evidence of carcinogenicity. Administration of glimepiride for 24 months in mice resulted in an increase in benign pancreatic adenomas, which was believed to be a result of dose-related chronic stimulation of the pancreas. In this experiment, the no-effect dose on adenoma formation in mice was 320 ppm or 46 to 54 mg/kg/day under complete diet conditions. Based on surface area, this is approximately 35 times the maximum recommended dose for humans of 8 mg once daily.
2) Glimepiride showed no mutations in a series of in vitro and in vivo mutation experiments.
3) There was no effect of glimepiride on fertility in male mice exposed at doses up to 2,500 mg/kg (>1,700 times the maximum recommended human dose based on surface area). Glimepiride did not affect fertility in male and female rats when administered at doses up to 4,000 mg/kg (approximately 4,000 times the maximum recommended human dose based on surface area).
5. How to save
Airtight container, stored at room temperature (1~30℃)
6. Packaging unit
30 tablets/bottle, 100 tablets/bottle
7. Period of use
36 months from date of manufacture
Product Updates
Total 5items
| No. | Product Name | Details | Date of Change | Download |
|---|---|---|---|---|
| 5 | Glimin Tab. | Glymine Tablets (Precautions for use) | 2017.10.27 | HWPGlimepiride single tablet system unification adjustment plan.hwp |
| 4 | Glimin Tab. | Glymine Tablets (effectiveness, dosage, precautions for use... | 2013.12.30 | HWP2012 Pharmaceutical Literature Re-evaluation (Glymin Tablet).hwp |
| 3 | Glimin Tab. | Glymine Tablets (Precautions for use) | 2009.10.07 | HWP9. Change order for permission (Glee Minjeong) (2009.10.07).hwp |
| 2 | Glimin Tab. | Glymine Tablets (Precautions for use) | 2008.08.26 | HWP9. Change order for permission (Glee Minjeong) (2008.08.26).hwp |
| 1 | Glimin Tab. | Glymine Tablets (Precautions for use) | 2006.04.03 | HWP9. Change order for permission (Glee Minjeong) (2006.04.03).hwp |